TitleProduct

Alemtuzumab

  • Price:

    Negotiable

  • minimum:

  • Total supply:

  • Delivery term:

    The date of payment from buyers deliver within days

  • seat:

    Shanghai

  • Validity to:

    Long-term effective

  • Last update:

    2018-12-16 18:25

  • Browse the number:

    376

Send an inquiries
+
Shanghai TheraMabs Bio-Technology Co.,Ltd
Contactaixin:

saimai2018(Mr.)  

Email:

sales@theramabs.com

telephone:

+86-21-58582603

phone:

13611999090

Arrea:

Shanghai

Address:

Room 156, 133# Dongzheng Road, Pudong Disrict, Shanghai, China

Website:

http://www.therapeuticmab.com/ http://saimai2018.chinamerchants-logistics.com/

+

Our product is the biosimilar of Alemtuzumab (216503-57-0), which is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) directed against the 21-28 kDa cell surface glycoprotein, CD52. It is an IgG1 kappa antibody with human variable framework and constant regions, and complementarity-determining regions from a murine (rat) monoclonal antibody. The biosimilar has an approximate molecular weight of 150 kDa, which is produced in mammalian cell (Chinese hamster ovary).


Features and Advantages:

Name

Biosimilar of Alemtuzumab

CAS NO.

216503-57-0

Type

Whole antibody

Source

Humanized (from rat)

Target

CD52

Clone

Monoclone

Molecular Weight

150 kDa

Formula

C6468H10066N1732O2005S40

Antibody Form

Purified immunoglobulin

Physical Form

Solution

Place of Origin

China (Mainland)

Storage

Sealed and stored at -70±15℃, away from light


Specifications:

The biosimilar of Alemtuzumab is supplied at a concentration of 30 mg/mL in the same buffer system with original drug (Campath) as a sterile, clear and colorless, preservative-free solution. Besides, Customized services are also available.

We can provide 65~130 KGs the biosimilar of Alemtuzumab bulk per year, Minimum order quantity for quality assessment is not less than 1g.


Applications:

Alemtuzumab, is a medication used to treat chronic lymphocytic leukemia (CLL), cutaneous T-cell lymphoma (CTCL), T-cell lymphoma, and multiple sclerosis. It is also used as an anti-rejection agent in some conditioning regimens for bone marrow transplantation, kidney transplantation and islet cell transplantation. 

The production and filling of the biosimilar of Alemtuzumab are in compliance with cGMP standards, but cannot be used for clinical trials and commercial use.


http://www.therapeuticmab.com/